HomeCompareMCGFX vs ABBV

MCGFX vs ABBV: Dividend Comparison 2026

MCGFX yields 44.51% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCGFX wins by $193.2K in total portfolio value
10 years
MCGFX
MCGFX
● Live price
44.51%
Share price
$9.71
Annual div
$4.32
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$295.6K
Annual income
$54,537.55
Full MCGFX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MCGFX vs ABBV

📍 MCGFX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCGFXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCGFX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCGFX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCGFX
Annual income on $10K today (after 15% tax)
$3,783.42/yr
After 10yr DRIP, annual income (after tax)
$46,356.92/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MCGFX beats the other by $25,300.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCGFX + ABBV for your $10,000?

MCGFX: 50%ABBV: 50%
100% ABBV50/50100% MCGFX
Portfolio after 10yr
$199.0K
Annual income
$39,654.66/yr
Blended yield
19.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MCGFX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCGFX buys
0
ABBV buys
0
No recent congressional trades found for MCGFX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCGFXABBV
Forward yield44.51%3.06%
Annual dividend / share$4.32$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$295.6K$102.3K
Annual income after 10y$54,537.55$24,771.77
Total dividends collected$229.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MCGFX vs ABBV ($10,000, DRIP)

YearMCGFX PortfolioMCGFX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$15,151$4,451.08$11,550$430.00+$3.6KMCGFX
2$22,514$6,302.68$13,472$627.96+$9.0KMCGFX
3$32,843$8,753.00$15,906$926.08+$16.9KMCGFX
4$47,076$11,933.33$19,071$1,382.55+$28.0KMCGFX
5$66,357$15,985.54$23,302$2,095.81+$43.1KMCGFX
6$92,060$21,058.65$29,150$3,237.93+$62.9KMCGFX
7$125,809$27,304.52$37,536$5,121.41+$88.3KMCGFX
8$169,489$34,873.09$50,079$8,338.38+$119.4KMCGFX
9$225,260$43,907.21$69,753$14,065.80+$155.5KMCGFX
10$295,566$54,537.55$102,337$24,771.77+$193.2KMCGFX

MCGFX vs ABBV: Complete Analysis 2026

MCGFXStock

Under normal circumstances, the fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in securities of large-capitalization companies. It primarily invests in equity securities. The fund may continue to hold securities of a portfolio company that subsequently drops below or appreciates above the large-capitalization threshold. It is non-diversified.

Full MCGFX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MCGFX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCGFX vs SCHDMCGFX vs JEPIMCGFX vs OMCGFX vs KOMCGFX vs MAINMCGFX vs JNJMCGFX vs MRKMCGFX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.